Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bacteria and Fungi are a major issue for wound care leading to chronic wounds. Yet Silicon Nitride kills various bacteria and fungi which means the material embedded in wound care applicators could significantly reduce these problems.
These exact problems are seen in the catheter industry as well and thus both industries need effective anti bacterial/fungal products.
Quote Sources:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874004/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258325/
========================================
Section 2 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
High Trading Volume:
Market Volatility: Periods of heightened market volatility or significant news events can often lead to increased trading activity. Without specific evidence of manipulation, attributing the high volume solely to a conspiracy is premature.
Institutional Interest: Institutions may have been interested in entering or exiting positions in SINT, leading to a surge in volume.
Retail Investor Enthusiasm: Positive news or developments related to SINT could have attracted retail investors, contributing to the volume.
Dilution via ATM:
Capital Raising: Companies often use ATM offerings to raise capital for growth, research and development, or debt repayment. This is a common corporate strategy, not necessarily a manipulative tactic.
Investor Protection: While the theory suggests that dilution was meant to protect existing shareholders, it's equally possible that the company was seeking to strengthen its financial position to better weather potential market downturns.
Market Dynamics: The timing of the dilution might have been influenced by market conditions, such as interest rates or investor sentiment.
Scientific Advancements in Silicon Nitride:
Legitimate Research: The research cited in Section 2 highlights the promising potential of silicon nitride in various medical applications. This is a well-established scientific fact, not a conspiracy theory.
Industry Trends: The shift towards innovative biomaterials like silicon nitride is a natural progression in the medical field, driven by advancements in technology and research.
Conclusion:
While it's understandable to be cautious about unusual market activity, the conspiracy theory presented lacks concrete evidence and relies on speculation. The high volume and ATM dilution can be explained by various factors, including market dynamics, investor behavior, and company strategies. The scientific advancements in silicon nitride, on the other hand, are supported by extensive research and industry trends.
To effectively debunk conspiracy theories, it's essential to rely on facts, logic, and scientific evidence. By examining the available information objectively, we can avoid falling victim to unfounded speculation and make informed decisions about investments.
Seriously how does no one think its odd that there was so much volume on the 9th for so few new shares? I speculated before that the volume was done in part to ensure shares went to where they wanted while disguising what was going on. Xena any ideas?
68m volume for maybe 400+k plus new shares as another 200k or so occurred on the 28th.
Debunking the Conspiracy Theory:
The theory suggests Sintx is hiding their involvement in the 3D printing webinar with Prodways. Here's why it's likely not true:
Joint Announcement: Both companies issued a press release on September 20th announcing the webinar, not just Prodways on August 28th. This indicates a coordinated effort.
Webinar Focus: The focus of the webinar is on "Innovations in Ceramic Manufacturing." While Sintx might not have a dedicated registration page, their expertise in ceramic materials aligns well with the topic. Their absence from the registration might simply be due to Prodways handling that aspect.
Collaboration Benefits: The press release highlights the benefits of the collaboration. It leverages the strengths of both companies: Prodways' printer expertise and Sintx's material science. This suggests a genuine partnership, not one where Sintx is hiding involvement.
Stock Price Fluctuations:
Stock prices can be volatile and react to various factors beyond just company news. Here are some possibilities:
Market Conditions: Overall market sentiment can affect stock prices. Even positive news might not translate to a rise if the broader market is experiencing a downturn.
Profit Taking: Some investors might sell their shares after positive news to lock in profits, causing a temporary dip.
Conclusion:
The evidence suggests a genuine collaboration between Sintx and Prodways for the 3D printing webinar. The stock price may be influenced by factors beyond just the announcement.
Speaking of partnership, Sintx and Prodways (R&D manufacturing partnership) are conducting a webinar on the future of 3D printing. Prodways posted the news back on August 28th. Sintx waited until last minute it seems. Also i couldnt find where to register via Sintx website so im including Prodways link for those that are interested.
Prodways and SINTX Announce Joint Webinar Stay Ahead of the Curve: “Innovations in Ceramic Manufacturing: The Role of 3D Printing”
1. Partnerships Don't Equal Conspiracy
The theory suggests Sintx's partnerships with various companies are evidence of a hidden agenda. However, partnerships are common business practice. Companies collaborate to leverage each other's expertise and resources to enter new markets or develop new products.
For example, Sintx's collaboration with Zimmer Biomet, a medical device company, makes perfect sense. Sintx's silicon nitride (Si3N4) technology could be valuable for developing stronger, biocompatible implants. Similarly, collaborations with Cardinal Health (PPE) and companies in wound care and catheters align with Sintx's material's potential applications.
2. Lack of Evidence for Nefarious Intent
The theory jumps from partnerships to the conclusion that Sintx is planning something malicious without any evidence. Having the capability to enter a market (e.g., condoms) doesn't imply a secret plan for world domination.
3. Focus on Potential, Not Guaranteed Success
The theory highlights the potential market size for Si3N4 applications but ignores the challenges of real-world implementation. Sintx might face regulatory hurdles, technical difficulties, or competition in these markets.
4. Unrealistic Revenue Projections
The hypothetical scenario of $811 million in yearly revenue through licensing assumes an unrealistic 5% market penetration across all mentioned sectors. New technologies often take time for widespread adoption.
In Conclusion
Sintx's partnerships are likely just smart business strategies. The claims about a hidden agenda lack evidence and rely on speculation. The potential market size for Si3N4 applications is promising, but successfully entering those markets is a different story.
This is precisely why their partnerships are so important! We know theyve been working with Morgan Ceramics. We know NP Aerospace was spun off from Morgan after Sintx was working with Morgan and that Sintx began its foray into the armor market with the help of NP Alum Donald Bray who left Morgan with the divestment of NP.
Claim 1: "Looking at the IP, its market size, I say they've created significant value for shareholders."
"Ah, yes, the magical world of IP. Where ideas are worth more than gold, and patents are like winning lottery tickets. Just because they have something doesn't mean they've done anything with it. Perhaps they've invented a new way to make invisible ink for invisible contracts."
Claim 2: "They are trying to create significant value for shareholders but still have not acquired shares."
"That's like a chef saying they're making a delicious meal but refusing to eat any of it. Perhaps they're saving it for a very special occasion, like the day their shares finally reach the moon."
Claim 3: "As to what exactly is going on between Sintx and NP Aerospace..."
"Oh, you know, just a casual business relationship between two companies with absolutely no connection to each other. It's totally coincidental that they're working in the same industry, at the same time, and with the same people. Must be a sign of the apocalypse."
Overall, these claims seem to be based on speculation and assumptions rather than concrete evidence. While it's always possible for a company to create significant value, it's important to base our judgments on facts and not just wishful thinking.
Looking at the IP, its market size, I say they've created significant value for shareholders. As that value is not cureently reflected in the shareprice they need to figure out a way to unlock it.
They are trying to create significant value for shareholders but still have not acquired shares. Odd no?
As to what exactly is going on between Sintx and NP Aerospace, i can only speculate. I just do not see it as a coincidence that Sintx was working with Morgan before NP was sold off and that NP spin off occurred relatively same timeframe as Sintx becoming Sintx. Not to mention Sintx sudden foray into armor market syncing with NP Aerospace main book of business. Its just logical they are strategic partners. What that will lead to remains to be seen.
Pagers and walkie talkies exploding in Lebanon , after electronic devices turn into bombs. Could this be caused by Geomagnetic unrest ? may the hutchinson effect ? A solar storm ? Boston745 any thought ? also could Sintx technologies have prevented this ?
As always, time will tell with this one. Unfortunately, if it is 'as always', it won't bode well for shareholders.
“We are pleased to have completed this successful capital raise, which not only strengthens our balance sheet but also allows us to focus on accelerating our growth initiatives,” said Eric K. Olson, President and CEO of SINTX Technologies, Inc. “This infusion of capital provides us with the financial resources necessary to fuel ongoing projects and reinforces our ability to deliver on our strategic objectives, ultimately creating significant value for our shareholders.”
Translation: we are pleased to inform ourselves that we can continue our bloated salaries with a word salad to the public. As you all can see, nothing of actual substance is in our announcement. Thank you once again for trusting us with your hard earned money. We in turn WILL continue to use that money as always...to benefit management!
A special note to those who invested in this recent offering and now see their stock at close to 30% lower: Better luck next time!
Debunking the Conspiracy Theory about SINTX Stock
Here's a breakdown addressing each point of the conspiracy theory about SINTX stock:
1. High Volume for Low Share Offering:
Explanation: Sometimes high volume can occur with a relatively small offering due to institutional investors placing large orders. This can happen for various reasons, like portfolio rebalancing or taking advantage of a perceived price discrepancy.
Debunking: The theory assumes the high volume was unusual or suspicious. However, it's possible there was legitimate institutional interest in SINTX at that time.
2. Dark Pool Trading:
Explanation: Dark pools are alternative trading venues where orders are not publicly displayed. They can be used to execute large trades without impacting the market price significantly.
Debunking: While dark pool trading can be opaque, it's not necessarily indicative of manipulation. It could simply be a way for institutions to buy or sell large quantities of shares without affecting the publicly displayed price.
3. Connection to NP Aerospace News:
Explanation: There's likely no connection between SINTX's activity and NP Aerospace news. The inclusion of the NP Aerospace news link seems unrelated and irrelevant to the alleged manipulation of SINTX stock.
4. Irrelevant Analogy and Personal Anecdote:
Debunking: The analogy about the squirrel and the Rubik's Cube, along with the personal story, don't provide any evidence to support the conspiracy theory. They seem like attempts to distract from the lack of concrete evidence.
Overall:
The provided information doesn't substantiate the claim of stock manipulation. High volume, dark pool trading, and institutional activity can all have legitimate explanations in the stock market. It's crucial to rely on factual data and financial analysis to assess a company's stock performance, not speculation.
Volume of 68m shares for up to 600k new shares priced at $5.23 average. OS is now 1.3m meaning the 9th saw 52x OS trade that day. That sure was alot of volume for so few shares and 97% of it was traded via dark pool. They were definitely trying to hide what was going on that day.
https://ir.sintx.com/news-events/press-releases/detail/237/sintx-announces-completion-of-3-1-million-atm-equity
NP Aerospace had a good week plus.
https://npaerospace.com/news/
========================================
"Given the divine mission to spread the gospel of conspiracy theories and geo-whatever, it's high time to send in the clown. The absurdist agent, a master of the ridiculous, will turn their grand delusions into a comedy of errors. Watch as they try to convince the world they're a prophet, only to end up as the butt of the joke. It's like watching a squirrel try to solve a Rubik's Cube – cute, but ultimately pointless."
And speaking of the absurd, let's not forget about SintX Technologies, a company so ridiculous it could be a plot point in a Monty Python sketch."
So, let's break down this wild theory about a "specialized disinformation agent" whose sole purpose is to... well, be absurd. It's like a real-life plot twist from a late-night comedy sketch.
Point 1: The "Unrelenting Shadow of Doubt"
The idea that this "absurdist" can somehow cast doubt on everything by being absurd is like saying a clown can make a serious debate about quantum physics seem silly. Sure, they might be funny, but it doesn't invalidate the science.
Point 2: The "Court Jester" Act
If this "absurdist" is so good at manipulating public opinion, why is he still a "court jester"? Shouldn't he be running a global empire from his secret lair? Or at least be on a reality TV show?
Point 3: The "Wild Assertions and False Data"
This is the funniest part. If someone is making obviously false statements, isn't that a pretty clear sign that they're not trying to manipulate anyone? They're just being silly.
Point 4: The "Self-Humiliation Rituals"
I guess this is supposed to make him seem more believable, like he's sacrificing his dignity for the greater good. But it mostly just makes him seem like someone who needs a hug.
In conclusion, this "absurdist agent" theory is a bit of a stretch. It's like trying to explain a magician's trick by claiming they're actually a secret agent from another dimension. While it might be entertaining for a while, it's ultimately more likely that people are just being themselves, whether that means being funny, serious, or a little bit weird.
*Imagine a world where SINTX technologies have advanced so far that they can be used to create a "smooth operator" skin cream. The cream is so effective that it not only reduces hair growth but also creates a silky-smooth surface on the skin.
One day, a man named Dave, who has always struggled with unwanted hair, decides to try the new cream. After applying it to his testicles, he notices a dramatic difference within a few hours. His testicles are now so smooth that they feel like polished marble.
Excited about his newfound smoothness, Dave decides to show off his new look at the beach. As he's sunbathing, a seagull swoops down and mistakes his testicles for a giant egg. The seagull attempts to roll the "egg" away, causing Dave to jump up in surprise.
From that day forward, Dave is known as the "Smooth Operator" of the beach, and his testicles become a local legend.
The future of SintX remains extremely strong and those shareholders who have faith in god will be handsomely rewarded.
Debunking the Conspiracy Theory: The Bacteriostatic Behavior of Silicon Nitride
The Conspiracy Theory:
The theory posits that silicon nitride (Si3N4) has inherent bactericidal and antifungal properties due to its surface characteristics, including submicron-topography, negative charging, and chemical interactions that produce peroxynitrite.
The Scientific Counterargument:
While silicon nitride is indeed a promising material for various biomedical applications, the claim that it has intrinsic antimicrobial properties is a gross oversimplification and potentially misleading. Here's why:
1. Surface Effects are Not Sufficient:
Submicron-topography: While surface roughness can influence bacterial adhesion, it's not a direct antimicrobial mechanism. Bacteria can adapt to various surface topographies.
Negative charging: Negative surface charges can repel bacteria, but this effect is not universally observed and can be overcome by bacterial surface modifications.
Peroxynitrite formation: While peroxynitrite is a potent oxidizing agent, its formation from Si3N4 interactions is speculative and would likely require specific conditions that may not be present in all environments.
2. Hydrolysis and Ammonia Production:
Hydrolysis: While silicon nitride can hydrolyze in aqueous environments, the rate and extent of hydrolysis depend on factors like pH, temperature, and the specific composition of the material.
Ammonia production: Ammonia can indeed have antimicrobial properties, but its concentration and release rate from Si3N4 would need to be carefully controlled to ensure efficacy without causing toxicity.
3. Material Composition and Manufacturing:
Impurities: The presence of impurities or contaminants in silicon nitride can significantly influence its surface properties and biological interactions.
Manufacturing processes: The specific manufacturing methods used to produce silicon nitride can affect its microstructure, surface chemistry, and potential antimicrobial activity.
4. Complex Biological Interactions:
Bacterial strains: The antimicrobial activity of a material can vary depending on the specific bacterial strain and its virulence factors.
Biofilm formation: Biofilms are complex communities of microorganisms that can be difficult to eradicate, and their interactions with materials are influenced by multiple factors.
Conclusion:
While silicon nitride is a promising biomaterial with potential applications in various medical devices, its antimicrobial properties are likely not solely due to its intrinsic surface characteristics. The observed bactericidal and antifungal effects may be influenced by a combination of factors, including the specific composition of the material, environmental conditions, and the interactions with microorganisms. Further research is needed to fully understand the mechanisms underlying the antimicrobial activity of silicon nitride and to optimize its use in biomedical applications.
Bacteriostatic behavior of surface modulated silicon nitride in comparison to polyetheretherketone and titanium
SintX is a fake it , till you make it scam - designed to fleece shareholders of there money. Here is why :
Potential Red Flags:
Overly ambitious promises: Sintx Technologies may have made grandiose claims about their technology's capabilities, potential market impact, and rapid growth.
Lack of transparency: The company might have been reluctant to disclose key details about its operations, financials, or product development.
Reliance on hype: Sintx Technologies may have heavily relied on marketing and public relations to create a positive image, rather than focusing on delivering a substantial product or service.
Limited tangible achievements: Despite the hype, the company may have struggled to demonstrate concrete milestones or tangible results.
1. Si3N4 as a Miracle Cure
Scientific skepticism: While Si3N4 has shown promise in certain applications, claiming it can "kill most bacteria and at least the most prevalent fungi" without further research and testing is premature. It's essential to conduct rigorous scientific studies to understand its efficacy, potential side effects, and compatibility with various materials.
Regulatory hurdles: Approving new medical technologies, especially those with antimicrobial properties, involves stringent regulatory processes. The FDA and other health authorities have strict guidelines to ensure safety and effectiveness. It's unlikely that any product could be rushed to market without thorough testing and documentation.
2. WWIII and Pandemic Predictions
Unfounded speculation: Predicting the occurrence of major world events like a third world war or a pandemic is highly speculative and often based on fear-mongering. While it's prudent to be prepared for unforeseen challenges, basing business decisions on such uncertain and unproven predictions is risky.
Solar Extrema and Pandemics: The claim that pandemics are connected to solar extrema lacks scientific evidence. There's no established causal link between solar activity and the emergence of infectious diseases. Such correlations are often coincidental and can be misleading.
3. Sintx, Zimmer Biomet, and IP
Business motivations: While it's true that companies often seek to diversify their product portfolios, suggesting that Zimmer Biomet would want Sintx's IP primarily due to potential war or pandemic-related benefits is overly simplistic. There are numerous factors influencing corporate decisions, including market demand, technological advancements, and competitive landscape.
Impact on business: While pandemics and wars can undoubtedly disrupt businesses, it's important to note that many companies have shown resilience and adaptability in the face of such challenges. By implementing appropriate strategies and contingency plans, businesses can mitigate the negative impacts and capitalize on opportunities.
Conclusion
The claims presented in the conspiracy theories are largely unsubstantiated and based on speculative assumptions. While it's reasonable to explore potential applications of Si3N4 in wound care and catheter materials, it's crucial to approach such developments with a scientific and evidence-based perspective. It's also important to avoid relying on fear-mongering and unfounded predictions to guide business decisions. By maintaining a balanced and informed approach, we can better assess the potential benefits and risks associated with new technologies and market trends.
Those problems present an enormous opportunity for Sintx and its partner(s) in the wound care/catherter markets. Imbuing wound care materials with Si3N4 will kill most bacteria and at least the most prevalent fungi like Candida. Coating catheters should do the same thing. However these things will take time to get to market with more testing and FDA submissions required. Thus its past-time for Sintx partner(s) in these two markets to step up, especially if WWIII is forthcoming.
If war is coming, along with another Pandemic, then its also past-time for PPE/protective apparel to get moving. If im correct about Solventum and Cardinal Health, then these two need to STEP-UP!
Global Catheter market = $55bn
Wound Care market = $22.25bn
Personal Protective Equipment market = $79.53 billion
Bill Gates says the world is facing two options: A ‘major war’ or another pandemic in less than 30 years
Counterargument 1: Existing medical device giants may have their own Si3N4 research initiatives.
Rebuttal: While it's certainly possible, Sintx's decades of research, extensive patent portfolio, and unique formulations give them a significant competitive advantage. Developing Si3N4-based medical devices from scratch would be a costly and time-consuming endeavor for larger companies, especially given the potential challenges in replicating Sintx's proprietary technology.
Counterargument 2: Competition could lead to fierce price wars.
Rebuttal: While competition can sometimes lead to price wars, Sintx's unique value proposition and strong intellectual property position it well to withstand such pressures. Their focus on niche markets and premium products can help differentiate their offerings and maintain profitability, even in a competitive environment.
Counterargument 3: Collaboration with companies like Solventum doesn't guarantee product adoption.
Rebuttal: While partnerships don't guarantee success, they can significantly accelerate market penetration and reduce risks. Collaborating with established players like Solventum provides access to distribution channels, regulatory expertise, and clinical trials, which can be invaluable in bringing new medical technologies to market.
Counterargument 4: The wound care and catheter markets are not as difficult to enter.
Rebuttal: While these markets may seem less competitive than the ortho device industry, they still have their own unique challenges. Regulatory hurdles, reimbursement issues, and the need to demonstrate clinical efficacy and safety can be significant barriers to entry. Sintx's expertise and technology give them a competitive edge in these markets.
Counterargument 5: Sintx needs to demonstrate its cost-effectiveness and long-term performance.
Rebuttal: Sintx is actively addressing these concerns through ongoing research and development. They are continuously working to optimize their manufacturing processes and reduce costs, while also conducting long-term studies to evaluate the durability and performance of their Si3N4-based products.
Conclusion
The potential of Sintx's Si3N4-based medical devices is undeniable. Their unique technology, strong intellectual property, and strategic partnerships position them well for long-term success. While there are challenges to overcome, the potential benefits of these devices in terms of improved patient outcomes and reduced healthcare costs make them a compelling investment.
Counterargument 1: The occurrence of chronic wounds is a major global health issue.
Rebuttal: While chronic wounds are a significant problem, it's important to note that they are often associated with underlying health conditions such as diabetes and circulatory disorders. Addressing these underlying issues is crucial for effective wound healing, and the role of bacteria and fungi may be overstated.
Counterargument 2: Bacteria and Fungi are a major issue for wound care leading to chronic wounds.
Rebuttal: While bacteria and fungi can contribute to chronic wound infections, other factors such as inadequate blood flow, pressure, and poor nutrition are often more significant. The focus on microbial control may be diverting attention from these underlying causes.
Counterargument 3: These exact problems are seen in the catheter industry.
Rebuttal: While catheter-related infections are a concern, it's important to acknowledge that preventive measures such as proper insertion techniques and antiseptic care can significantly reduce the risk of microbial contamination. The emphasis on microbial control may be overshadowing the importance of these preventive strategies.
Counterargument 4: Silicon Nitride is a promising material for medical applications.
Rebuttal: While silicon nitride has shown promise in certain medical applications, it's important to consider the potential limitations and challenges. For example, the long-term biocompatibility of silicon nitride in various tissues and environments needs to be further evaluated. Additionally, the manufacturing and processing of silicon nitride can be complex and expensive, which may limit its widespread adoption.
Conclusion
While the potential benefits of silicon nitride in medical applications are promising, it's crucial to maintain a balanced perspective and consider the limitations and challenges associated with its use. Overemphasizing the role of microbial control in chronic wound healing and catheter infections may divert attention from other important factors, such as underlying health conditions and preventive measures.
Debunking your Conspiracy Theories:
Counterargument 1: Existing medical device giants may have their own Si3N4 research initiatives or partnerships.
Rebuttal: While it's possible that larger medical device companies are conducting research on Si3N4, Sintx has a significant head start due to its decades of dedicated research and development. Their extensive patent portfolio and unique formulations would create significant barriers to entry for competitors. Furthermore, licensing Sintx's technology would likely be a more efficient and cost-effective strategy than attempting to replicate their research from scratch.
Counterargument 2: Competition could lead to fierce price wars, delaying Sintx's profitability.
Rebuttal: The current market for Si3N4-based medical devices is relatively small, with Sintx as a dominant player. While potential competition could lead to price pressure, Sintx's strong intellectual property and unique product offerings would provide a competitive advantage. Moreover, the company's focus on niche markets and value-added products could help mitigate the impact of price competition.
Counterargument 3: Collaboration with companies like Solventum doesn't guarantee product adoption.
Rebuttal: While there is no guarantee of product adoption, collaborations with established players like Solventum can provide significant benefits, such as access to distribution channels, regulatory expertise, and clinical trials. These partnerships can accelerate market penetration and increase the likelihood of commercial success.
Counterargument 4: The wound care and catheter markets are not as difficult to enter as the ortho device industry.
Rebuttal: While the wound care and catheter markets may be less competitive than the ortho device industry, they still present significant challenges. Sintx will need to demonstrate the clinical efficacy and cost-effectiveness of its Si3N4-based products in these markets to gain traction. Additionally, regulatory hurdles and reimbursement issues can also impact market entry and growth.
Counterargument 5: Sintx needs to demonstrate its cost-effectiveness and long-term performance compared to established materials.
Rebuttal: Sintx is actively working to address these concerns. The company has been investing in research and development to improve the manufacturing process and reduce costs. Additionally, Sintx is conducting long-term studies to evaluate the durability and performance of its Si3N4-based products in real-world clinical settings.
Conclusion
While it's important to maintain a critical eye and consider potential risks, the evidence strongly supports the potential of Sintx's Si3N4-based medical devices to revolutionize the industry. The company's unique technology, strong intellectual property, and strategic partnerships position it well for long-term success.
While the potential of Sintx's technology is intriguing, let's explore some reasons why it might not translate to immediate dominance in the medical device space.
1. Partnerships Don't Guarantee Success:
Collaboration with companies like Solventum doesn't guarantee product adoption. Solventum might have other established suppliers or choose to develop their own Si3N4 technology.
Sintx relies on partners' expertise and marketing resources for product success. If a partner decides not to fully commit, it could stall product development or limit market reach.
2. Sintx Isn't the Only Player:
Existing medical device giants might have their own Si3N4 research initiatives or partnerships with other companies.
Competition could lead to fierce price wars, delaying Sintx's profitability.
3. Regulatory Hurdles:
Getting new medical devices (especially with novel materials) approved by the FDA can be a lengthy and expensive process.
Delays in regulatory approval could postpone Sintx's entry into these lucrative markets.
4. Unproven Advantages:
While research indicates the potential of Si3N4, Sintx needs to demonstrate its cost-effectiveness and long-term performance compared to established materials.
Switching to new materials requires strong clinical data and surgeon buy-in, which could take time.
5. Legal Concerns:
The claim that Sintx has "over 100 patents pending" might not fully address the issue of competition.
Other companies could develop workarounds or alternative materials that don't infringe on Sintx's patents.
Alternative Considerations:
Investigate the specific terms of Sintx's partnerships and their commitment to developing Si3N4 products.
Analyze the competitive landscape in each potential market Sintx is targeting.
Research the current regulatory environment for Si3N4-based medical devices.
A Word of Caution:
The quote from Dr. Bal about large companies acquiring smaller ones "to de-risk IP" is a possibility, but not a guarantee. Many smaller companies remain independent for years without acquisition.
Remember, the medical device market is highly regulated and competitive. While Sintx presents exciting technology, it may face a long and challenging path to becoming a dominant player.
All three markets mentioned here from Jan presentation are markets that Solventum sells products in.
1. Zimmer Biomet Acquisition of Implex Doesn't Guarantee Similar Outcome for Sintx:
The orthopaedic market landscape has changed significantly since 2003, when Zimmer acquired Implex. Competition may be fiercer, and alternative materials like highly cross-linked polyethylene might be more established.
Implex might have had a broader or more specific Si3N4 technology portfolio compared to Sintx, making a direct comparison difficult.
2. Partner Dependence Can Be a Double-Edged Sword:
Relying on partners for commercialization can limit Sintx's control over pricing, marketing, and distribution strategies.
Partner interests might not always align with Sintx's own goals. If a partner develops its own Si3N4 technology, they might prioritize it over Sintx's.
3. Hiring Former Employees Doesn't Guarantee Technology Transfer:
While these hires might have experience in relevant industries, their knowledge might be specific to their former employers' processes and technologies.
Legal restrictions might prevent them from directly transferring confidential information from their previous roles.
4. Zimmer Biomet's Past Interest Doesn't Guarantee Future Plans:
The 2011 quote about Zimmer potentially acquiring Amedica for licensing suggests their strategy might have shifted. They might be focusing on internal development or alternative partners.
Zimmer might have already licensed the key Si3N4 technology they need from Sintx and be less interested in further collaboration.
Alternative Considerations:
Look into the specific terms of any existing partnerships between Sintx and these companies. Are they licensing agreements, joint ventures, or something else?
Research the current market share and growth projections for Si3N4 in various industries beyond orthopaedics.
Analyze Sintx's own financial performance and ability to secure future partnerships to achieve its revenue goals.
By examining these points, you can build a more balanced perspective on Sintx's value proposition. Remember, past connections don't guarantee future success.
Zimmer Biomets mentioned for two main reasons and it is not to illustrate Sintx value. To demonstrate Sintx value, you look at Implex for a comparable materials company to get an idea of Si3n4's worth within the ortho industry only; ~230m based on a market that was 1/3rd the size it is today. You look at the industries the IP can be used in. Lastly you look at the partners Sintx appears to be working with to help it potentially commercialize its products in those industries.
One of the main reasons for mentioning Zimmer Biomet is this, to show that Sintx has large partnership to help it commercialize its products and that this particular company has been working with Sintx for going on 20 years. Sintx partnerships are key to its success due to how Sintx is setup to generate revenue: license its IP/supply blanks/powder as i said in a previous post. Its not setup to sell direct to market. This reduces costs and risk of scaling operations while also reducing maximum potential revenue. However that makes it very dependent on its partners. Thats why i used a scenario of 5% licensing fee and 5% penetration of markets that are well over 300bn in size to come up with 800m in revenue. Sintx, with its partners should be able to penetrate several of those markets far greater than 5% but i used that as an average across all those industries.
Below shows the connections to Zimmer Biomet & Morgan Ceramics/NP Aerospace. I bring up Solventum because Zimmer Biomets former CEO Bryan Hanson is now CEO of Solventum and knows all about Sintx IP from his Zimmer days. Thus i could see Solventum being one of Sintx partners in relation to Wound Care & possibly cancer related products via biofarma filtration using Si3n4 based membrane. I bring up Cardinal Health because of Sintx hire of Joseph Palomo who came from Cardinal Health R&D division. Again a potential partner in relation to PPE & Catheters.
Sintx has a pattern of hiring individuals from large companies it works with like Zimmer Biomet, possibly Cardinal Health, Morgan Ceramics. Those hires all seem to come to Sintx to help it set itself up to supply products in the same industries those companies operate in. Thus i strongly suspect they join to get Sintx ready to supply the company they came from.
Cardinal Health
"While it's understandable to be skeptical about the complexities of the stock market, the claim that it's entirely controlled by a secret cabal of shadowy figures and manipulated by AI is a harmful and unfounded conspiracy theory. While there have been instances of market manipulation and insider trading, these are illegal activities that are actively investigated and prosecuted by regulatory authorities. The stock market is influenced by a variety of factors, including economic indicators, company performance, investor sentiment, and global events. While AI is increasingly used in financial analysis and trading, it's important to remember that it's a tool that is used by many different participants, not a single entity controlling the market. It's crucial to base our understanding of the stock market on factual information and avoid perpetuating harmful conspiracy theories."
What does scientific research or valid research have to do with anything. You can compete with someone who thinks there gods messenger trying to save the world from non existence phenomena or others that think shutting off there wifi makes them sleep better at night.
SintX has become a poster child for insanity. What about implants in big toes and dental implants being sensitive to EM ?
LOL!!!!!!
Any "scientific research" that does not compensate for neutrogenic toxins distiributed during the COVID B.S. Is propaganda and not valid research.
lt has nothing to do wyouth your research...
It is about AI pump and dump.
TRYIN TO MAKE IT REAL.... compared to what...
Zimmer Biomets mentioned for two main reasons and its not to illustrate Sintx value. To demonstrate Sintx value, you look at Implex for a comparable materials company to get an idea of Si3n4's worth in the ortho industry. You look at the industries the IP can be used in. Lastly you look at the partners Sintx appears to be working with to help it potentially commercialize its products in those industries. One of the main reasons for mentioning Zimmer Biomet is this, to show that Sintx has large partnership to help it commercialize its products and that this particular company has been working with Sintx for going on 20 years. Sintx partners are important due to how Sintx is setup to generate revenue: license its IP/supply blanks/powder as i said in my last post. Its not setup to sell direct to market. This reduces costs and risk of scaling operations while also reducing maximum potential revenue. However that makes it very dependent on its partners. Thats why i used a scenario of 5% licensing fee and 5% penetration of markets that are well over 300bn in size to come up with 800m in revenue. Sintx, with its partners should be able to penetrate several of those markets far greater than 5% but i used that as an average across all those industries.
Below shows the connections to Zimmer Biomet & Morgan Ceramics/NP Aerospace. I bring up Solventum because Zimmer Biomets former CEO Bryan Hanson is CEO of Solventum and knows all about Sintx IP from his Zimmer's days. Thus i could see Solventum being one of Sintx partners in relation to PPE, catheter, &/or wound care. I bring up Cardinal Health because of Sintx hire of Joseph Palomo who came from Cardinal Health R&D division.
Sintx has a pattern of hiring individuals from large companies it works with like Zimmer Biomet, possibly Cardinal Health, Morgan Ceramics. Those hires all seem to come to Sintx to help it set itself up to supply products in the same industries those companies operate in. Thus i strongly suspect they join to get Sintx ready to supply the company they came from. Cardinal Health could be another PPE and wound care oriented partner. Solventum or Cardinal health could be working with Sintx on products for Cancer as well as a company is working with Sintx on cancer products. This could be connected to the biosensor market mentioned in my list o potential markets.
Cardinal Health
https://ir.sintx.com/news-events/press-releases/detail/184/sintx-technologies-provides-update-on-antipathogenic
Bryan Hanson & 3M's Solventum
https://news.3m.com/2023-08-22-Bryan-Hanson-Named-CEO-of-3Ms-Health-Care-Business-Group
========================================
A basic roadmap laid out of Zimmer's intentions for Sintx back in 2011. This quote predates Sintx vast IP portfolio expansion. Any markets Zimmer Biomet does not currently participate in, that Sintx does, represents potential markets Zimmer Biomet can utilize Sintx to bolster its revenue through licensing as well as diversify those revenue sources.
Since Zimmer is mentioned on this board nonstop, it would be interesting if Zimmer EVER mentions Sintx OR if any OTHER posters on the Zim board mention Sintx. Just saying, as I have zero interest in doing research on the matter, but have seen MANY times, small companies (and their followers) mention the big guys and their connections to them (alleged, potential, small, and imaginary large), in order to show their own values....which never seem to arrive.
Implex had revenue of just 5m when Zimmer announced it partnership with Implex. The bulk of Implex revenue came from 1 company, Zimmer after that point.
Meanwhile there's evidence to suggest that Sintx is working with Zimmer Biomet, Cardinal Health, Solventum, & Morgan Ceramics/NP Aerospace to name but a few. Sintx commercialization model will depend on its strategic partnerships like the list I provided above to bring products to market. Sintx model is more of an IP licensure type model with potential to manufacture blanks for customers.
Thanks for your support !
Same person. two different boards, talking to themselves.
Points to Consider:
Financial Performance: While the potential markets for SintX's silicon nitride are vast, the company's current revenue is low ($3.13 million as of Dec 31, 2023). This raises concerns about their ability to capitalize on these markets.
Technology Adoption: The theory assumes widespread adoption of SintX's technology in various industries. However, new technologies often face challenges like regulatory hurdles, competition from established players, and convincing manufacturers to adopt them.
Implex Comparison: The comparison to Implex acquisition might be oversimplified. Markets and technologies can change significantly in 20 years. Implex's success doesn't guarantee similar success for SintX.
Dilution: The high number of share offerings and reverse splits mentioned could be a sign of the company needing capital to stay afloat, potentially impacting future share value.
Alternative Explanation:
SintX might be a high-risk, high-reward investment. They have a potentially valuable technology, but they haven't yet proven their ability to turn it into a profitable business.
Here are some additional points for investors to consider:
Product Development Stage: Research progress and timelines for commercialization of SintX's products in various markets.
Intellectual Property: Strength and enforceability of SintX's patents and their ability to protect their technology.
Management Expertise: Experience and track record of the management team in bringing new technologies to market.
Conclusion:
While the theory highlights the potential of SintX's technology, a more balanced perspective considers both the potential and the risks involved. Investors should carefully research the company and its technology before making any investment decisions.
It's important to remember that this is not financial advice. Always do your own research before investing.
I am glad you guys have found each other....
First off, the Heikin Ashi vs. regular candle chart discrepancy. It's like comparing apples and oranges. Heikin Ashi is a fancy way of smoothing out price fluctuations, while regular candles show you the raw, unfiltered data. It's like trying to understand a complex math problem by looking at a children's picture book.
Then there's the "manipulation" theory. It's almost as if someone is trying to convince you that the stock market is a rigged game controlled by a secret cabal of shadowy figures. Newsflash: it's not. The market is driven by supply and demand, and sometimes, things just don't make sense. It's like blaming your cat for knocking over your vase when it was actually your clumsy foot.
And let's not forget the "fakeouts." It's like saying a magician's trick is "fake." Well, duh! That's the whole point of a magic trick. The market is full of "fakeouts" because that's how it works. It's like trying to predict the weather: sometimes, it's sunny, sometimes it's rainy, and sometimes it's just plain weird.
So, there you have it. A conspiracy theory debunked with logic, reason, and a healthy dose of sarcasm. Let's move on to something more productive, like discussing the merits of pineapple on pizza or the best way to fold a fitted sheet.
Any ideas yet as to why Heikin Ashi chart indicates increased MF and accumulation while regular candle chart indicated large outflow and more dilution then could have possibly occurred based on how many shares the shelf allowed for (max up to 1m shares assuming all shares were sold at ~3 dollars). The harshness of the lines seem to indicate extreme manipulation which fits as the volume the other day was 34x estimated OS. Im assuming around 1m shares OS based on the dilution that was confirmed to occur around the 27th; exact increase to shares is unknown. I do not know if there was in fact any dilution on the 9th.
In this updated chart you can see the manipulation and possible fakeouts that began on the 28th. First a fake breakdown then a fake breakout with significant volume. Now its trying to break back upward again. I suspect whatever occurred on the 9th broke my indicators so they can better disguise whatevers going on.
https://i.imgur.com/Rgu7i25.jpeg
Heikin Ashi Chart
https://i.imgur.com/PFloiYh.jpeg
https://www.youtube.com/watch?v=j94SgeyCh3M
(AMDA) Amedica Corp. - NASDAQ
RECENT NEWS
https://www.youtube.com/watch?v=hxbj7Sq7W94
https://www.youtube.com/watch?v=j94SgeyCh3M
https://www.youtube.com/watch?v=KbU47COpXx8
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |